News

175 from 27 different countries participated in the Steno Symposium in May. The topic for the symposium was ‘Novel Insights in Diabetes Mellitus and its Complications’. Several researchers in this field gave a presentation on the topic, among them 11 speakers from abroad.

05 January
On January 1st 2009 the research area has been changed, as three of the research teams are organisational belonging under Hagedorn Research Institute. The three teams are researching in molecular genetics (Oluf Pedersen), immunology type 1 diabetes (Thomas Mandrup-Poulsen) and genetics protetmic (Flemming Pociot).

2008
06 November
Vibeke Zoffmann, PhD MPH RN, has been appointed as senior researcher at Steno Diabetes Center. She has developed a flexible program for young adults 18-35 years based on Guided Self-Determination. She will soon start implementing this program in the outpatient clinic.
Reflection sheets can be downloaded from here.


04 November
Results from NIP - avaible on www.sundhed.dk
The Danish National Indicator Project (NIP) measures the quality of care provided by the hospitals to groups of patients with specific medical conditions as diabetes. Steno Diabetes Center has reported data for all our patients in the clinic (data like blodd pressure, HbA1c, lipids).
Read about NIP

16 September
Award to Gitte Andersen
Gitte Andersen, MSc, PhD. and post.doc., has received the talent award 2008 from the Bagger Soerensen Foundation. She is given the award due to her exceptional contribution in investigating the molecular disease processes in genes that is leading to obesity, type 2 diabetes and heart diseases.

28 August
New initiatives with focus on treatment
In collaboration with the managements of Steno Diabetes Center (SDC) and Hagedorn Research Institute (HRI), Novo Nordisk has decided to implement a number of initiatives to ensure the continued strengthening of treatment, research, development and education in diabetes. This will enable the two institutions to maintain and jointly further develop their international leadership in these important areas. A Steno Lifestyle Centre will be established as one of the initiatives. Read more

27 August
The Steno-2 Follow-up Study: Intensive global risk intervention reduces all-cause- and cardiovascular mortality in patients with type 2 diabetes
Steno-2 Study, a prospective, randomized, open-label, blinded trial has previously shown that intensified multifactorial intervention-with the use of renin-angiotensin system (RAS) blockers, aspirin, lipid-lowering agents and a more tight glucose regulation compared with usual multifactorial treatment in line with national guidelines cuts the risk of microvascular complications and nonfatal cardiovascular disease by half in patients with type 2 diabetes and microalbuminuria. Read more

29 May
The Frontiers symposim - an unqualified succes
Frontiers in Diabetes Research and Clinical Diabetology 2008 has just been held successfully in Copenhagen with 180 participants from 25 different nations. This year’s programme was very varied with topics as diabetes burden in the society, impact of hyperglycaemia, treatment modalities in type 2 diabetes, GLP-1 based therapies, feet need friends and painful diabetic neuropathy. Steno Education Center was the organizer of the symposium and was praised for the scientific programme as well as for the social programme that included a bike ride in the Deer garden and a visit to Steno Diabetes Center.